Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?

2020 ◽  
Vol 52 (10) ◽  
pp. 3051-3057
Author(s):  
Manabu Okada ◽  
Toshihide Tomosugi ◽  
Kenta Futamura ◽  
Takahisa Hiramitsu ◽  
Norihiko Goto ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Early Treatment ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Antibody Mediated Rejection ◽  
Hla Antibody

De Novo Renal Carcinoma in Renal Transplant Recipients: Effect of Early Treatment

2009 ◽  
Vol 41 (8) ◽  
pp. 3314-3316 ◽  
Author(s):  
X. Tillou ◽  
M. Demailly ◽  
F. Hakami ◽  
P.-F. Westeel ◽  
F. Saint ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Early Treatment ◽  
Renal Carcinoma ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients

Early Versus Late Acute Antibody-Mediated Rejection in Renal Transplant Recipients

2013 ◽  
Vol 96 (1) ◽  
pp. 79-84 ◽  
Author(s):  
Christina Dörje ◽  
Karsten Midtvedt ◽  
Hallvard Holdaas ◽  
Christian Naper ◽  
Erik H. Strøm ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Antibody Mediated Rejection

scholarly journals 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

2007 ◽  
Vol 20 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Helio Tedesco-Silva ◽  
Stefan Vitko ◽  
Julio Pascual ◽  
Josette Eris ◽  
John C. Magee ◽  
...  
Keyword(s):  
Renal Transplant ◽  
De Novo ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document